Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines

被引:61
作者
Chorvat, RJ
Bakthavatchalam, R
Beck, JP
Gilligan, PJ
Wilde, RG
Cocuzza, AJ
Hobbs, FW
Cheeseman, RS
Curry, M
Rescinito, JP
Krenitsky, P
Chidester, D
Yarem, JA
Klaczkiewicz, JD
Hodge, CN
Aldrich, PE
Wasserman, ZR
Fernandez, CH
Zaczek, R
Fitzgerald, LW
Huang, SM
Shen, HL
Wong, YN
Chien, BM
Quon, CY
Arvanitis, A
机构
[1] Dupont Merck Pharmaceut Co, Expt Stn, Dept Chem & Phys Sci, Wilmington, DE 19880 USA
[2] Dupont Merck Pharmaceut Co, Expt Stn, Dept Biol Sci, Wilmington, DE 19880 USA
[3] Stine Haskell Res Ctr, Drug Metab & Pharmacokinet Sect, Newark, DE 19714 USA
关键词
D O I
10.1021/jm980224g
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis and CRF receptor binding affinities of several new series of N-aryltriazolo- and -imidazopyrimidines and -pyridines are described. These cyclized systems were prepared from appropriately substituted diaminopyrimidines or -pyridines by nitrous acid, orthoester, or acyl halide treatment. Variations of amino (ether) pendants and aromatic substituents have defined the structure-activity relationships of these series and resulted in the identification of a variety of high-affinity agents (K-i's < 10 nM). On the basis of this property and lipophilicity differences, six of these compounds (4d,i,n,x, 8k, 9a) were initially chosen for rat pharmacokinetic (PK) studies. Good oral bioavailability, high plasma levels, and duration of four of these compounds (4d,i,n,x) prompted further PK studies in the dog following both iv and oral routes of administration. Results from this work indicated 4i,x had properties we believe necessary for a potential therapeutic agent, and 4i(1) has been selected for further pharmacological studies that will be reported in due course.
引用
收藏
页码:833 / 848
页数:16
相关论文
共 32 条
[1]   PTERIDINE STUDIES .5. THE MONOSUBSTITUTED PTERIDINES [J].
ALBERT, A ;
BROWN, DJ ;
WOOD, HCS .
JOURNAL OF THE CHEMICAL SOCIETY, 1954, (NOV) :3832-3839
[2]   Non-peptide corticotropin-releasing hormone antagonists: Syntheses and structure-activity relationships of 2-anilinopyrimidines and -triazines [J].
Arvanitis, AG ;
Gilligan, PJ ;
Chorvat, RJ ;
Cheeseman, RS ;
Christos, TE ;
Bakthavatchalam, R ;
Beck, JP ;
Cocuzza, AJ ;
Hobbs, FW ;
Wilde, RG ;
Arnold, C ;
Chidester, D ;
Curry, M ;
He, LQ ;
Hollis, A ;
Klaczkiewicz, J ;
Krenitsky, PJ ;
Rescinito, JP ;
Scholfield, E ;
Culp, S ;
De Souza, EB ;
Fitzgerald, L ;
Grigoriadis, D ;
Tam, SW ;
Wong, YN ;
Huang, SM ;
Shen, HL .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (05) :805-818
[3]  
BAKTHAVATCHALAM R, 1996, 212 NAT M AM CHEM SO
[4]   A CORTICOTROPIN-RELEASING FACTOR ANTAGONIST REVERSES THE STRESS-INDUCED CHANGES OF EXPLORATORY-BEHAVIOR IN MICE [J].
BERRIDGE, CW ;
DUNN, AJ .
HORMONES AND BEHAVIOR, 1987, 21 (03) :393-401
[5]   CORTICOTROPIN-RELEASING FACTOR ELICITS NALOXONE SENSITIVE STRESS-LIKE ALTERATIONS IN EXPLORATORY-BEHAVIOR IN MICE [J].
BERRIDGE, CW ;
DUNN, AJ .
REGULATORY PEPTIDES, 1986, 16 (01) :83-93
[7]   INTRAVENTRICULAR CORTICOTROPIN-RELEASING FACTOR ENHANCES BEHAVIORAL-EFFECTS OF NOVELTY [J].
BRITTON, DR ;
KOOB, GF ;
RIVIER, J ;
VALE, W .
LIFE SCIENCES, 1982, 31 (04) :363-367
[8]  
BRITTON KT, 1988, PSYCHOPHARMACOLOGY, V94, P306
[9]  
CHEN YL, 1994, Patent No. 13676
[10]  
CHEN YL, 1994, Patent No. 13677